Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-FLT3 CAR-T in Relapsed/Refractory AML
NCT05023707Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAA05 in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Number of Adverse Events at 12 months. Status: unknown.
02
Drugs
TAA05
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05023707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023707.